wpostServer: http://css.washingtonpost.com/wpost
Robert H. Smith School of Business
The Motley Fool

Market Foolery Featured Podcasts

  • MarketFoolery 04.23.2014
    On today’s show the guys talk about Amazon’s newly announced deal with HBO and what it means for the site. Plus they talk earnings from Intuitive Surgical, Yum! Brands, and more.
  • MarketFoolery: 04.22.2014
    Netflix rises on strong 1st quarter numbers and a well-executed price increase.  Valeant Pharmaceuticals makes a $45 billion bid for Allergan.  Plus, we analyze the latest results from McDonald’s and the new “Pay To Quit” program at Amazon.
  • MarketFoolery: 04.21.2014
    Hasbro shares rise on 1st-quarter profits.  LinkedIn tops the 300 million member mark.  And we dip into the Fool Mailbag to discuss the prospects for Airbnb’s potential IPO.
Capital Business
Posted at 04:09 PM ET, 03/18/2013

MedImmune gains 300 jobs in AstraZeneca consolidation

Gaithersburg-based MedImmune will gain 300 jobs as parent company AstraZeneca consolidates its overall global research and development operations, the companies announced Monday.

The announcement comes as AstraZeneca designated the Gaithersburg subsidiary one of three global research and development centers for the company, as well as the center of its marketing and specialty care commercial operations for the United States.

In January, AstraZeneca named Bahija Jallal chief executive of MedImmune and said its Montgomery County offices would serve as a primary location for the company’s biologics research and development.

In addition to Gaithersburg, AstraZeneca will maintain research and development hubs in Cambridge, United Kingdom and Mölndal, Sweden.

“The strategic centers will also allow us to tap into important bioscience hotspots, providing more of our people with easy access to leading-edge academic and industry networks, scientific talent and valuable partnering opportunities,” AstraZeneca chief executive Pascal Soriot said in a statement.

MedImmune counts roughly 2,000 employees in Gaitherburg and another 540 in Cambridge, Jallal said in an interview, including staff on both the science and business sides of the company.

Jallal said that biologics make up about 50 percent of AstraZeneca’s drug development pipline and most of that research takes place in Gaithersburg, meaning MedImmune should continue to play a central role in AstraZeneca’s growth as a company.

AstraZeneca paid $15.6 billion for MedImmune in the summer of 2007, a hefty price tag that to date remains unrivaled by other local biotechnology acquisitions.

“AstraZeneca frankly placed a huge importance into MedImmune when they bought MedImmune and I think since then there was a serious commitment,” Jallal said. “This is another step in that commitment to MedImmune . . . and the investment they’re doing in biologics.”

The restructuring announced Monday will result in 1,200 jobs leaving the company’s Wilmington, Del. location. About 650 of those positions will be eliminated, 80 will go to Boston and another 170 will be relocated to other AstraZeneca sites.

“The proposals are designed to co-locate teams to improve collaboration and put science and the patient at the heart of everything the company does,” AstraZeneca said in a statement. “The changes will also simplify the company’s global site footprint.”

By  |  04:09 PM ET, 03/18/2013

 
Read what others are saying
     

    © 2011 The Washington Post Company